170 related articles for article (PubMed ID: 9370078)
1. Inhibitors of tyrosine kinase.
Klohs WD; Fry DW; Kraker AJ
Curr Opin Oncol; 1997 Nov; 9(6):562-8. PubMed ID: 9370078
[TBL] [Abstract][Full Text] [Related]
2. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase activity of purified recombinant cytoplasmic domain of platelet-derived growth factor beta-receptor (beta-PDGFR) and discovery of a novel inhibitor of receptor tyrosine kinases.
Zaman GJ; Vink PM; van den Doelen AA; Veeneman GH; Theunissen HJ
Biochem Pharmacol; 1999 Jan; 57(1):57-64. PubMed ID: 9920285
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors of the class 1 receptor tyrosine kinase family.
Cockerill GS; Lackey KE
Curr Top Med Chem; 2002 Sep; 2(9):1001-10. PubMed ID: 12171567
[TBL] [Abstract][Full Text] [Related]
5. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
Gangjee A; Yang J; Ihnat MA; Kamat S
Bioorg Med Chem; 2003 Nov; 11(23):5155-70. PubMed ID: 14604679
[TBL] [Abstract][Full Text] [Related]
7. Flk-1 as a target for tumor growth inhibition.
Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
[TBL] [Abstract][Full Text] [Related]
8. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
[TBL] [Abstract][Full Text] [Related]
9. 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase.
Thompson AM; Connolly CJ; Hamby JM; Boushelle S; Hartl BG; Amar AM; Kraker AJ; Driscoll DL; Steinkampf RW; Patmore SJ; Vincent PW; Roberts BJ; Elliott WL; Klohs W; Leopold WR; Showalter HD; Denny WA
J Med Chem; 2000 Nov; 43(22):4200-11. PubMed ID: 11063616
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases.
Showalter HD; Kraker AJ
Pharmacol Ther; 1997; 76(1-3):55-71. PubMed ID: 9535169
[TBL] [Abstract][Full Text] [Related]
11. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
12. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.
Hamby JM; Connolly CJ; Schroeder MC; Winters RT; Showalter HD; Panek RL; Major TC; Olsewski B; Ryan MJ; Dahring T; Lu GH; Keiser J; Amar A; Shen C; Kraker AJ; Slintak V; Nelson JM; Fry DW; Bradford L; Hallak H; Doherty AM
J Med Chem; 1997 Jul; 40(15):2296-303. PubMed ID: 9240345
[TBL] [Abstract][Full Text] [Related]
14. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
Teller S; Krämer D; Böhmer SA; Tse KF; Small D; Mahboobi S; Wallrapp C; Beckers T; Kratz-Albers K; Schwäble J; Serve H; Böhmer FD
Leukemia; 2002 Aug; 16(8):1528-34. PubMed ID: 12145694
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
16. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
Bäckman U; Christofferson R
Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
[TBL] [Abstract][Full Text] [Related]
17. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
19. Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.
Ghosh S; Liu XP; Zheng Y; Uckun FM
Curr Cancer Drug Targets; 2001 Aug; 1(2):129-40. PubMed ID: 12188886
[TBL] [Abstract][Full Text] [Related]
20. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
